These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 28814855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
    Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS.
    Lancet; 2008 Jun 14; 371(9629):2013-8. PubMed ID: 18555912
    [Abstract] [Full Text] [Related]

  • 3. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
    Esposito A, Valentino MR, Bruzzese D, Bocchino M, Ponticiello A, Stanziola A, Sanduzzi A.
    Pulm Pharmacol Ther; 2016 Apr 14; 37():85-8. PubMed ID: 26970503
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J, van Agteren JE, Carson-Chahhoud KV.
    Cochrane Database Syst Rev; 2018 Dec 19; 12(12):CD012346. PubMed ID: 30566235
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
    Janjua S, Mathioudakis AG, Fortescue R, Walker RA, Sharif S, Threapleton CJ, Dias S.
    Cochrane Database Syst Rev; 2021 Jan 15; 1(1):CD013198. PubMed ID: 33448349
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.
    Respir Res; 2019 May 27; 20(1):104. PubMed ID: 31133026
    [Abstract] [Full Text] [Related]

  • 7. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H, Htet A, Moe S.
    Cochrane Database Syst Rev; 2017 Jun 20; 6(6):CD011897. PubMed ID: 28631387
    [Abstract] [Full Text] [Related]

  • 8. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 9. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
    Hooper C, Calvert J.
    Int J Chron Obstruct Pulmon Dis; 2008 Mar 06; 3(4):659-69. PubMed ID: 19281081
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
    Yuan L, Dai X, Yang M, Cai Q, Shao N.
    Int J Chron Obstruct Pulmon Dis; 2016 Mar 06; 11():1477-83. PubMed ID: 27418821
    [Abstract] [Full Text] [Related]

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 13. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM, Mavergames C, Walters JA.
    Cochrane Database Syst Rev; 2013 Oct 15; (10):CD010177. PubMed ID: 24127118
    [Abstract] [Full Text] [Related]

  • 14. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
    Calverley PM, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 15; 14():2733-2744. PubMed ID: 31819405
    [Abstract] [Full Text] [Related]

  • 15. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 15; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 16. Carbocisteine for acute exacerbations of COPD.
    Waller P, Suissa S.
    Lancet; 2008 Nov 08; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
    [No Abstract] [Full Text] [Related]

  • 17. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C, Chong J, Poole P.
    Cochrane Database Syst Rev; 2012 Jul 11; (7):CD009285. PubMed ID: 22786525
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC, Poole P.
    Cochrane Database Syst Rev; 2013 Nov 28; (11):CD009764. PubMed ID: 24288145
    [Abstract] [Full Text] [Related]

  • 19. Carbocisteine for acute exacerbations of COPD.
    Mohapatra PR, Aggarwal D.
    Lancet; 2008 Nov 08; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
    [No Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J, Leung B, Poole P.
    Cochrane Database Syst Rev; 2013 Nov 04; (11):CD002309. PubMed ID: 24190161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.